New biodegradable polymers for delivering multiple cancer drugs
Multifunctional Biodegradable Zwitterionic Polymer-Drug Conjugates for Multidrug Co-Delivery
This study is looking at new ways to deliver cancer treatments using special biodegradable materials that can safely carry multiple drugs at once, aiming to make cancer therapy more effective and with fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11084287 on NIH RePORTER |
What this research studies
This research focuses on developing innovative biodegradable polymer-drug conjugates that can effectively deliver multiple cancer therapies simultaneously. By creating zwitterionic polymers that are both biocompatible and biodegradable, the project aims to overcome the limitations of traditional drug delivery systems that often cause side effects or are ineffective. The researchers will synthesize these new polymers and study how they interact with biological environments and cells to ensure they can deliver drugs safely and effectively. This approach could lead to improved treatment options for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing treatment for cancer who may benefit from advanced drug delivery systems.
Not a fit: Patients with non-cancerous conditions or those who are not currently receiving cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer method for delivering cancer treatments, potentially improving patient outcomes.
How similar studies have performed: Other research has shown promise in using biodegradable polymers for drug delivery, indicating that this approach has potential for success.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Cheng, Chong — State University of New York at Buffalo
- Study coordinator: Cheng, Chong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.